XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:        
Total revenues $ 6,599 $ 6,260 $ 12,951 $ 12,850
Costs and expenses:        
Cost of goods sold 1,442 1,442 2,843 2,866
Research and development expenses 1,407 1,102 2,854 2,280
Acquired in-process research and development expenses 236 330 717 338
In-process research and development impairment 0 0 0 2,700
Selling, general and administrative expenses 1,849 1,357 3,168 2,440
Total costs and expenses 4,934 4,231 9,581 10,624
Operating income 1,665 2,029 3,370 2,226
Interest expense (230) (242) (459) (480)
Other income (expense), net 152 (284) (22) (395)
Income before income taxes 1,588 1,503 2,888 1,351
Income tax expense (549) (368) (865) (204)
Net income 1,039 1,135 2,024 1,147
Net loss attributable to noncontrolling interest 6 9 32 16
Net income attributable to Gilead $ 1,045 $ 1,144 $ 2,055 $ 1,163
Basic earnings per share attributable to Gilead (in dollars per share) $ 0.84 $ 0.91 $ 1.65 $ 0.93
Shares used in basic earnings per share attributable to Gilead calculation (in shares) 1,249 1,256 1,249 1,255
Diluted earnings per share attributable to Gilead (in dollars per share) $ 0.83 $ 0.91 $ 1.63 $ 0.92
Shares used in diluted earnings per share attributable to Gilead calculation (in shares) 1,258 1,260 1,260 1,261
Product sales        
Revenues:        
Total revenues $ 6,564 $ 6,138 $ 12,870 $ 12,672
Royalty, contract and other revenues        
Revenues:        
Total revenues $ 35 $ 122 $ 81 $ 178